Disrupted Healthcare – 22 Deals and Investments This Week

VC Deals (10 deals, $240M)

Tizona Therapeutics Inc., a South San Francisco-based immunotherapy startup focused on cancer and autoimmune diseases, has raised $43 million in Series B funding. Abingworth and Canaan Partners co-led the round, and were joined by Lightstone Ventures and return backers MPM Capital, Amgen Ventures, Astellas Venture Management and InterWest Partners

Capella Bioscience Ltd., a UK-based developer of monoclonal antibody medicines, has raised £11 million in Series A funding. Backers include Advent Life Sciences, Medicxi Ventures, and Osage University Partners

Aprea AB, a Sweden-based developer of anti-cancer therapies targeting the tumor suppressor protein p53, has raised €46 million in Series B funding.Versant Ventures and 5AM Ventures co-led the round, and was joined by Sectoral Asset Management, HealthCap, KDev Investments and Rosetta Capital

CBC Biotechnologies Inc., a Tampa, Fla.-based startup that uses synthetic biology to create pharmaceutical-grade cannabinoids, has raised $7 million in Series A funding led by Tuatara Capital

4Tech Inc., an Ireland-based developer of a transcatheter treatment for tricuspid regurgitation, has raised $29 million in Series B funding. Valianceand RMM co-led the round, and were joined by NeoMed Management

Constant Therapy, a Boston-based provider of customized brain rehabilitation apps, has raised $2 million in Series A funding. Golden Seeds led the round, and was joined by Kapor Capital, Launchpad Venture Group, Pond Capital and Community Health Network of Connecticut

HealthTell, a four-year-old, Arizona-based blood diagnostics startup that can allegedly assess a patient’s immune response to 30 conditions with a single drop of blood, has raised $26 million in what looks to become a $35.5 million funding round, according to an SEC filing flagged by MedCity News. The company’s previous investors include Vital Venture Capital, Paladin Capital Group,Acadia Woods Partners, Cambridge Global Capital and the Broe Group

Aspyrian Therapeutics, a six-year-old, San Diego, Ca.-base biotech company that’s developing precision targeted oncologic drugs to treat solid tumors, has raised $40 million as part of a Series B financing that was mostly provided by Rakuten CEO Hiroshi Mikitani, through his personal investment companies

Ahmedabad-based (India) online medicine delivery aggregator eSwasthya has raised an undisclosed amount of seed investment from Hemang Sahani, a member of Lothal Angel Ventures #healthtechasia

Bangalore-based (India) clinical supplies provider PinkBlue.in has raised about $156K in a seed round funding from TermSheet.io, a transaction-focused service provider for startups and investors #healthtechasia

Sleep tracking company Eight (formerly known as Luna) raised $6 million in seed funding from Y Combinator, Yunqui Partners, Azure Capital, Cota Capital, Comcast Ventures, Vast Ventures, Stanford University, Galvanize Ventures, Idea Bulb VC, and Scribd co-founder Jared Friedman

Raleigh, North Carolina-based heart rate sensor company Valencell has raised $8.4 million more in a round that totaled $11 million

PE Deals (3 deals)

Bodytech Corp., a Colombia-based gym chain in Latin America, has secured an undisclosed amount of growth equity funding from L Catterton

Immucor Inc., a Norcross, Ga.-based provider of transfusion and transplantation diagnostics, has acquired Sirona Genomics, a Mountain View, Calif.-based developer of gene sequencing typing applications. No financial terms were disclosed. Immucor is a portfolio company of TPG Capital

Apax Partners has agreed to acquire a 50.1% stake in the respiratory products business of Becton Dickinson & Co. (NYSE: BDX), via a joint venture valued at around $500 million

IPO Deals (5 deals)

PLX Pharma Inc., a Houston-based developer of an oral drug delivery system that is designed to increase safety and efficacy, has withdrawn its IPO registration due to “market conditions.” The company had planned to price 3.8 million shares at between $17 and $19 per share, with Maxim Group serving as sole underwriter. Shareholders include Integra Venture (6.6% pre-IPO stake) and Aurus Bios Fondo de Inversion Privado (6.3%)

Senseonics, a Germantown, Md.-based provider of glucose monitoring devices, has set its IPO terms to 18.2 million shares being offered at between $3.10 and $3.50 per share. The company’s stock is currently traded on the OTCQB under ticker symbol SENH, and it plans to relist on the NYSE MKT under symbol SENS. Leerink Partners and Canaccord Genuity are serving as lead underwriters. Senseonics reports a $24 million net loss on $38 million in revenue for the first nine months of 2015, and is backed by such firms as New Enterprise Associates (33% stake), Delphi Ventures (13.4%), HealthCare Ventures (7.4%), Roche Finance (10.5%) and Energy Capital (9.9%)

Spring Bank Pharmaceuticals Inc., a Milford, Mass.-based developer of drugs based on a proprietary small molecule nucleic acid hybrid, has set its IPO terms to 2.858 million shares being offered at between $13 and $15 per share. The pre-revenue company plans to trade on the Nasdaq under ticker symbol SBPH, with William Blair listed as left lead underwriter

Corvus Pharmaceuticals Inc., a Burlingame, Calif.-based developer of immuno-oncology therapies, has set its IPO terms to 4.7 million shares being offered at between $15 and $17 per share. It would have an initial market cap of around $327 million were it to price in the middle of its range. The pre-revenue company plans to trade on the Nasdaq under ticker symbol CRVS, with Credit Suisse and Cowen & Co. serving as lead underwriters. Shareholders include OrbiMed Advisors (29.98% pre-IPO stake), Novo AS (15.84%), Adams Street Partners (15.84%) and Fidelity (8.18%)

Valeritas Inc., a Bridgewater, N.J.-based maker of insulin delivery devices for Type 2 diabetics, has formally withdrawn IPO registration papers. The company had planned to offer 5 million shares at between $14 and $16 per share (market cap of $237 million if it priced in the middle). Piper Jaffray and Leerink Partners were serving as lead underwriters. Valeritas reported nearly a $65.5 million net loss for 2014 on $13.5 million in revenue. Shareholders include Welsh Carson Anderson & Stowe, Onset Ventures and Pitango Venture Capital

Other Deals (4 deals)

Toshiba Corp. (Tokyo: 6502) named Canon Inc. (Tokyo: 7751) as the preferred bidder for its healthcare unit. Other bidders has included Permira (with Konica Minolta) and KKR (with Mitsui & Co.)

Frazier Healthcare Partners has hired RBC Capital Markets to find a buyer for PCI Pharma Services, a Philadelphia-based provider of outsourced packaging and clinical trial supply services to the pharma industry, according toReuters. The deal could be valued at around $1 billion

Spark Therapeutics (Nasdaq: ONCE) has acquiredGenable Technologies, an Ireland-based gene therapy startup, for more than $15 million in cash and stock

Teva Pharmaceuticals (NYSE: TEVA) has gotten EU approval for its proposed $40.5 billion purchase of the generics unit of Allergan (NYSE: AGN), after Teva agreed to sell some of its European operations

Sources: Term Sheet, Financial Times, StrictlyVC, TechinAsia, CrunchBase, TechCrunch, Bloomberg, MobiHealthNews

The Propell Group

#healthtech #asia